Core Points - The U.S. government has reached an agreement with Eli Lilly (LLY.US) and Novo Nordisk (NVO.US) to significantly reduce the prices of GLP-1 weight loss drugs in the Medicare, Medicaid, and self-pay markets, aiming to enhance accessibility for millions of Americans [1][2] - Current prices for GLP-1 drugs range from $500 to $1,000 per month, but under the new agreement, prices will be lowered to between $149 and $350 per month, with Medicare and Medicaid beneficiaries being the first to benefit [1][2] - The agreement includes a commitment from the government to provide a three-year tariff exemption for the companies, with Novo Nordisk pledging an additional $10 billion investment in the U.S. [3] Pricing Details - The oral GLP-1 weight loss drug currently under development will be priced at $149 per month for Medicare and Medicaid, while injectable versions will be approximately $245 per month [2] - Eli Lilly's Zepbound will be available at $299 per month for the lowest dose and $449 for higher doses in the self-pay market [2] - A cap of $50 per month on out-of-pocket costs for Medicare patients is set to significantly reduce the financial burden on elderly patients [2] Market Impact - The price reduction is expected to improve drug accessibility for approximately 40 million Medicare beneficiaries, along with millions of self-pay users [3] - Deutsche Bank analysts estimate that if the price cap is set at $150 per month, Eli Lilly's oral GLP-1 drug orforglipron could potentially add 15 million new patients, compared to the current 2.7 million patients using Zepbound [3] - This agreement is viewed as a critical milestone in the government's drug pricing reform efforts, following previous initiatives involving major pharmaceutical companies like Pfizer (PFE.US) and AstraZeneca (AZN.US) [3]

The president said it's a triumph for the American patient. Is it. So like most of these are most favored nations deals that Trump is doing with drug companies.You know, we don't know the full the full details of this yet. The basic parameters, you know, are similar to other deals that Trump has done so far with companies like Pfizer or AstraZeneca. This is kind of the obesity drug deal that Trump is doing.They're talking about prices they offered starting for some Medicare patients with certain conditions, ...

Core Insights - The recent drug pricing deals negotiated by the Trump administration are seen as a potential win for American patients, particularly in relation to obesity drugs from companies like Eli Lilly and Novo Nordisk [1][3] - The specifics of the pricing structure for Medicare patients remain unclear, with initial offers reported at $245 per month with a $50 co-pay for certain conditions [2][7] - The agreements spare Eli Lilly and Novo Nordisk from tariffs for three years and provide them with priority review vouchers from the FDA for their new drugs, allowing for faster market access in exchange for lower cash prices [3][5] Pricing and Accessibility - The companies involved are expected to adopt a most favored nation pricing model, which may lead to lower prices for Medicaid and direct cash purchases, but the full parameters of these agreements are not yet disclosed [5][6] - There is uncertainty regarding how many patients will benefit from these lower prices, especially those who are currently insured and may not need the drugs [6][10] - The expansion of eligibility for Medicare patients to access these obesity drugs at lower prices is a significant question, particularly for those with co-morbidities like pre-diabetes and heart conditions [6][8][10] Future Considerations - The potential long-term savings for the U.S. healthcare system by treating patients with weight loss drugs is a topic of discussion, especially for those at risk of serious health issues [8] - The details of how the Medicaid care program will function and the coverage of obesity drugs under Medicare are still pending clarification [9][10] - A briefing is expected to provide more information on the plans and pricing structures, which could impact the overall accessibility of these drugs [7][10]

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

Core Insights - Novo Nordisk's experimental obesity drug CagriSema has shown significant blood pressure reduction in a late-stage trial, indicating potential health benefits beyond weight loss [1] Group 1 - The late-stage trial results suggest that CagriSema may provide cardiovascular benefits, which could enhance its marketability [1] - Novo Nordisk aims to demonstrate that CagriSema can address multiple health issues associated with obesity, potentially expanding its therapeutic applications [1] - The company is focusing on the broader implications of its obesity treatment, which may attract more attention from healthcare providers and patients [1]

Core Insights - Novo Nordisk presented new post hoc analyses from the phase 3 REDEFINE 1 trial for CagriSema, an investigational treatment for obesity, highlighting its potential cardiovascular risk reduction effects [1][15]. Group 1: Clinical Efficacy - CagriSema treatment resulted in a reduction of systolic blood pressure by -10.9 mmHg over 68 weeks, outperforming semaglutide (–8.8 mmHg) and placebo (–2.1 mmHg) [2][6]. - Approximately 40% of participants on blood pressure medications were able to reduce or stop their medication during the trial [2][6]. - CagriSema demonstrated a significant reduction in high-sensitivity C-reactive protein (hsCRP) by –68.9%, compared to –55.4% with semaglutide and –16.0% with placebo, indicating anti-inflammatory effects [3][6]. Group 2: Cardiovascular Risk - The treatment reduced the proportion of individuals at intermediate-to-high risk of developing atherosclerotic cardiovascular disease (ASCVD) within the next 10 years [6]. - A dedicated trial (REDEFINE 3) is ongoing to further investigate CagriSema's effects on cardiovascular outcomes in patients with established cardiovascular disease [4][6]. Group 3: Safety Profile - Safety data from the REDEFINE 1 trial indicated low discontinuation rates due to adverse events, with 6% for CagriSema compared to 3.7% for placebo [4]. - Adverse events were primarily gastrointestinal, with nausea (55% vs. 12.6% for placebo), constipation (30.7% vs. 11.6%), and vomiting (26.1% vs. 4.1%), mostly mild-to-moderate in severity [4]. Group 4: Product Information - CagriSema is a fixed-dose combination of cagrilintide (2.4 mg) and semaglutide (2.4 mg), being investigated for adults with overweight or obesity and type 2 diabetes [7][8]. - The REDEFINE 1 trial involved 3,417 adults with obesity or overweight and one or more obesity-related comorbidities, without type 2 diabetes [8].

Core Insights - President Trump announced agreements with Eli Lilly and Novo Nordisk to reduce prices for GLP-1-based obesity and diabetes drugs and expand Medicare and Medicaid coverage starting mid-2026 [1][3] Group 1: Agreements and Pricing - Eli Lilly and Novo Nordisk will provide GLP-1 medications to Medicare and Medicaid for $245 per month, with Medicare patients paying a $50 copay for approved drugs [3] - Initial costs for existing injectables like Wegovy and Zepbound will be $350 per month, decreasing to $245 within two years [4] - Upcoming oral versions are expected to be priced at $145 per month through Medicare, Medicaid, or TrumpRx once approved [4] Group 2: Coverage and Eligibility - The initiative will start as a Medicare Part D pilot program, covering about 6.6 million Medicare enrollees with obesity or related health risks [5][6] - Eligibility will focus on individuals with obesity, prediabetes, heart disease, or kidney complications [6] Group 3: Company Developments - Eli Lilly will receive relief from potential new tariffs and be exempt from additional drug pricing programs under the Trump administration [6] - Eli Lilly announced additional price cuts on its LillyDirect platform, reducing Zepbound's price to $299 per month for the lowest dose [7] - Eli Lilly's Phase 2 trial of eloralintide showed significant weight reductions, with plans to initiate Phase 3 studies by year-end [8]

President Trump announced his administration secured deals with Eli Lilly and Novo Nordisk to slash prices for their blockbuster weight-loss drugs, Zepbound and Wegovy, in exchange for tariff relief https://t.co/HPSBbvUzWw https://t.co/5lpeQcoKSJ ...

Novo Nordisk expects global sales to decline by low-single-digit percentage in 2026 after the drugmaker unveiled a deal on Thursday to slash prices of popular GLP-1 weightloss drugs for U.S. governme... ...

Core Viewpoint - Novo Nordisk reported year-over-year growth in sales and earnings for Q3 but downgraded its full-year outlook for the fourth time, indicating ongoing challenges in its GLP-1 diabetes and obesity product lines [1][4]. Sales and Earnings Outlook - The company now expects full-year 2025 sales growth of 8% to 11% at constant exchange rates, down from a previous forecast of 8% to 14%. Operating profits are projected to grow between 4% and 7%, reduced from 10% to 16% [2][4]. Reasons for Guidance Downgrade - The downgrade is primarily due to lower growth expectations for GLP-1 products such as Ozempic, Rybelsus, and Wegovy. Compounding of cheaper, unapproved GLP-1 drugs is affecting market share, with Novo Nordisk losing 9% of its global market share over the past year [4][5][8]. Competitive Landscape - Increased competition from Eli Lilly's Mounjaro and Zepbound has contributed to the loss of market share for Novo Nordisk's GLP-1 products. The rise of compounded GLP-1 drugs is also a significant concern, with over 1 million patients in the U.S. reportedly using these alternatives [5][8]. Additional Costs - Novo Nordisk anticipates incurring additional costs related to the pending acquisitions of Akero Therapeutics and Omeros, which are also impacting its operating profit guidance [6]. Strategic Focus - The new CEO, Maziar "Mike" Doustdar, indicated that the company is "sharpening our focus" by discontinuing several pipeline programs and prioritizing core areas of diabetes and obesity. The company plans to reduce approximately 9,000 positions as part of this transformation [7]. Future Prospects - Novo Nordisk aims to secure FDA approval for a pill version of Wegovy by the end of 2025, which management believes could expand its market presence [9].